Alnylam Pharmaceuticals
4 clinical trials · 4 recruiting · INDUSTRY
Trials by Alnylam Pharmaceuticals
RECRUITINGPhase 1NCT06585449
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Sponsor: Alnylam PharmaceuticalsEnrolling: 6619 locations
Huntington's Disease
RECRUITINGNCT07358078
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with...
Sponsor: Alnylam PharmaceuticalsEnrolling: 20003 locations
Transthyretin Amyloidosis With Cardiomyopathy
RECRUITINGPhase 2NCT07465224
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Sponsor: Alnylam PharmaceuticalsEnrolling: 401 location
Type 2 Diabetes Mellitus (T2DM)
RECRUITINGNCT05040373
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Sponsor: Alnylam PharmaceuticalsEnrolling: 107 locations
Hereditary Transthyretin-mediated (hATTR) AmyloidosisPolyneuropathy